Cell migration is regulated by AGE-RAGE interaction in human oral cancer cells in vitro

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Ko, Shun Yao ^a   Ko, Hshin An ^a   Shieh, Tzong Ming ^b   Chang, Weng Cheng ^a   Chen, Hong I ^a   Chang, Shu Shing ^a   Lin, I Hsuan ^a  

^a CHANG JUNG CHRISTIAN UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; GELATINASE A; GELATINASE B; MITOGEN ACTIVATED PROTEIN KINASE; 2-(2-AMINO-3-METHOXYPHENYL)-4H-1-BENZOPYRAN-4-ONE; AGER PROTEIN, HUMAN; FLAVONOID; MMP2 PROTEIN, HUMAN; MMP9 PROTEIN, HUMAN; SMALL INTERFERING RNA;

ARTICLE; CANCER PROGNOSIS; CARCINOGENESIS; CELL MIGRATION; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULAR INTERACTION; MOUTH CANCER; ORAL CANCER CELL LINE; PROTEIN EXPRESSION; REGULATORY MECHANISM; RNA INTERFERENCE; SAS CELL LINE; SIGNAL TRANSDUCTION; TUMOR INVASION; ADULT; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL MOTION; CELL PROLIFERATION; COMPLICATION; DIABETES MELLITUS; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MALE; METASTASIS; MOUTH TUMOR; PATHOLOGY; TUMOR CELL LINE;

ADULT; ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTOR; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DIABETES COMPLICATIONS; DIABETES MELLITUS; FEMALE; FLAVONOIDS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MOUTH NEOPLASMS; NEOPLASM METASTASIS; RNA, SMALL INTERFERING;

EID: 84908042856     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0110542     Document Type: Article

References (49)

1. Ahmad S, Moinuddin, Dixit K, Shahab U, Alam K, et al. (2011) Genotoxicity and immunogenicity of DNA-advanced glycation end products formed by methylglyoxal and lysine in presence of Cu2+. Biochem Biophys Res Commun 407: 568-574.
2. Akhter F, Salman Khan M, Shahab U, Moinuddin, Ahmad S (2013) Biophysical characterization of ribose induced glycation: a mechanistic study on DNA perturbations. Int J Biol Macromol 58: 206-210.
3. Shahab U, Tabrez S, Khan MS, Akhter F, Saeed M, et al. (2014) Immunogenicity of DNA-advanced glycation end product fashioned through glyoxal and arginine in the presence of Fe: Its potential role in prompt recognition of diabetes mellitus auto-antibodies. Chem Biol Interact 219C: 229-240.
4. Ahmad S, Moinuddin, Habib S, Shahab U, Alam K, et al. (2014) Autoimmune response to AGE modified human DNA: Implications in type 1 diabetes mellitus Journal of Clinical & Translational Endocrinology 1: 66-72.
5. Ahmad S, Khan MS, Akhter F, Khan A, Ashraf JM, et al. (2014) Glycoxidation of biological macromolecules: A critical approach to halt the menace of glycation. Glycobiology.
6. Ahmad S, Shahab U, Baig MH, Khan MS, Srivastava AK, et al. (2013) Inhibitory effect of metformin and pyridoxamine in the formation of early, intermediate and advanced glycation end-products. PLoS One 8: e72128.
7. Ahmad S, Moinuddin, Shahab U, Habib S, Salman Khan M, et al. (2014) Glycoxidative damage to human DNA: Neo-antigenic epitopes on DNA molecule could be a possible reason for autoimmune response in type 1 diabetes. Glycobiology 24: 281-291.
8. Luth HJ, Ogunlade V, Kuhla B, Kientsch-Engel R, Stahl P, et al. (2005) Age-and stage-dependent accumulation of advanced glycation end products in intracellular deposits in normal and Alzheimer's disease brains. Cereb Cortex 15: 211-220.
9. Ahmad S, Akhter F, Moinuddin, Shahab U, Khan MS (2013) Studies on glycation of human low density lipoprotein: a functional insight into physicochemical analysis. Int J Biol Macromol 62: 167-171.
10. Mustafa I, Ahmad S, Dixit K, Moinuddin, Ahmad J, et al. (2012) Glycated human DNA is a preferred antigen for anti-DNA antibodies in diabetic patients. Diabetes Res Clin Pract 95: 98-104.
11. Tan KC, Shiu SW, Chow WS, Leng L, Bucala R, et al. (2006) Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes. Diabetologia 49: 2756-2762.
12. Basta G, Schmidt AM, De Caterina R (2004) Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res 63: 582-592.
13. Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414: 813-820.
14. Ahmed N (2005) Advanced glycation endproducts-role in pathology of diabetic complications. Diabetes Res Clin Pract 67: 3-21.
15. Bhawal UK, Ozaki Y, Nishimura M, Sugiyama M, Sasahira T, et al. (2005) Association of expression of receptor for advanced glycation end products and invasive activity of oral squamous cell carcinoma. Oncology 69: 246-255.
16. Cai Q, Li BY, Gao HQ, Zhang JH, Wang JF, et al. (2011) Grape seed procyanidin b2 inhibits human aortic smooth muscle cell proliferation and migration induced by advanced glycation end products. Biosci Biotechnol Biochem 75: 1692-1697.
17. Takino J, Yamagishi S, Takeuchi M (2010) Cancer malignancy is enhanced by glyceraldehyde-derived advanced glycation end-products. J Oncol 2010: 739852.
18. Yamamoto K, Kitayama W, Denda A, Sasahira T, Kuniyasu H, et al. (2006) Expression of receptor for advanced glycation end products during rat tongue carcinogenesis by 4-nitroquinoline 1-oxide and effect of a selective cyclooxygenase-2 inhibitor, etodolac. Pathobiology 73: 317-324.
19. Sasahira T, Kirita T, Bhawal UK, Yamamoto K, Ohmori H, et al. (2007) Receptor for advanced glycation end products (RAGE) is important in the prediction of recurrence in human oral squamous cell carcinoma. Histopathology 51: 166-172.
20. Kuniyasu H, Oue N, Wakikawa A, Shigeishi H, Matsutani N, et al. (2002) Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer. J Pathol 196: 163-170.
21. Abe R, Yamagishi S (2008) AGE-RAGE system and carcinogenesis. Curr Pharm Des 14: 940-945.
22. Kim JY, Park HK, Yoon JS, Kim SJ, Kim ES, et al. (2008) Advanced glycation end product (AGE)-induced proliferation of HEL cells via receptor for AGE-related signal pathways. Int J Oncol 33: 493-501.
23. Kuniyasu H, Chihara Y, Kondo H (2003) Differential effects between amphoterin and advanced glycation end products on colon cancer cells. Int J Cancer 104: 722-727.
24. Okamoto T, Yamagishi S, Inagaki Y, Amano S, Koga K, et al. (2002) Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin. FASEB J 16: 1928-1930.
25. Kuniyasu H, Chihara Y, Takahashi T (2003) Co-expression of receptor for advanced glycation end products and the ligand amphoterin associates closely with metastasis of colorectal cancer. Oncol Rep 10: 445-448.
26. Wu CH, Wu TY, Li CC, Lui MT, Chang KW, et al. (2010) Impact of diabetes mellitus on the prognosis of patients with oral squamous cell carcinoma: a retrospective cohort study. Ann Surg Oncol 17: 2175-2183.
27. Vairaktaris E, Goutzanis L, Yapijakis C, Vassiliou S, Spyridonidou S, et al. (2009) Diabetes enhances the expression of H-ras and suppresses the expression of EGFR leading to increased cell proliferation. Histol Histopathol 24: 531-539.
28. Ko SY, Lin YP, Lin YS, Chang SS (2010) Advanced glycation end products enhance amyloid precursor protein expression by inducing reactive oxygen species. Free Radic Biol Med 49: 474-480.
29. Jin Q, Chen H, Luo A, Ding F, Liu Z (2011) S100A14 stimulates cell proliferation and induces cell apoptosis at different concentrations via receptor for advanced glycation end products (RAGE). PLoS One 6: e19375.
30. Vairaktaris E, Spyridonidou S, Goutzanis L, Vylliotis A, Lazaris A, et al. (2007) Diabetes and oral oncogenesis. Anticancer Res 27: 4185-4193.
31. Girtan M, Zurac S, Staniceanu F, Bastian A, Popp C, et al. (2009) Oral epithelial hyperplasia in diabetes mellitus. Rom J Intern Med 47: 201-203.
32. Vairaktaris E, Kalokerinos G, Goutzanis L, Yapijakis C, Derka S, et al. (2008) Diabetes enhances cell proliferation but not Bax/Bcl-2-mediated apoptosis during oral oncogenesis. Int J Oral Maxillofac Surg 37: 60-65.
33. Abe R, Shimizu T, Sugawara H, Watanabe H, Nakamura H, et al. (2004) Regulation of human melanoma growth and metastasis by AGE-AGE receptor interactions. J Invest Dermatol 122: 461-467.
34. Patel BP, Shah PM, Rawal UM, Desai AA, Shah SV, et al. (2005) Activation of MMP-2 and MMP-9 in patients with oral squamous cell carcinoma. J Surg Oncol 90: 81-88.
35. Patel BP, Shah SV, Shukla SN, Shah PM, Patel PS (2007) Clinical significance of MMP-2 and MMP-9 in patients with oral cancer. Head Neck 29: 564-572.
36. Zhu P, Yang C, Chen LH, Ren M, Lao GJ, et al. (2010) Impairment of human keratinocyte mobility and proliferation by advanced glycation end products-modified BSA. Arch Dermatol Res 303: 339-350.
37. Zhu P, Ren M, Yang C, Hu YX, Ran JM, et al. (2011) Involvement of RAGE, MAPK and NF-kappaB pathways in AGEs-induced MMP-9 activation in HaCaT keratinocytes. Exp Dermatol 21: 123-129.
38. Zhang F, Banker G, Liu X, Suwanabol PA, Lengfeld J, et al. (2011) The novel function of advanced glycation end products in regulation of MMP-9 production. J Surg Res 171: 871-876.
39. Buckley ST, Medina C, Kasper M, Ehrhardt C. (2010). interplay between RAGE, CD44, and focal adhesion molecules in epithelial-mesenchymal transition of alveolar epithelial cells. Am J Physiol Lung Cell Mol Physiol 300: L548-L559.
40. Welten AG, Schalkwijk CG, ter Wee PM, Meijer S, van den Born J, et al. (2003). Single exposure of mesothelial cells to glucose degradation products (GDPs) yields early advanced glycation end-products (AGEs) and a proinflammatory response. Perit Dial Int 23:213-221.
41. Donato R, Sorci G, Riuzzi F, Arcuri C, Bianchi R, et al. (2009) S100B's double life: intracellular regulator and extracellular signal. Biochim Biophys Acta 1793: 1008-1022.
42. Leclerc E, Fritz G, Weibel M, Heizmann CW, Galichet A (2007) S100B and S100A6 differentially modulate cell survival by interacting with distinct RAGE (receptor for advanced glycation end products) immunoglobulin domains. J Biol Chem 282: 31317-31331.
43. Riuzzi F, Sorci G, Beccafico S, Donato R (2012) S100B engages RAGE or bFGF/FGFR1 in myoblasts depending on its own concentration and myoblast density. Implications for muscle regeneration. PLoS One 7: e28700.
44. Xu X, Zhu H, Wang T, Sun Y, Ni P, et al. (2014) Exogenous high-mobility group box 1 inhibits apoptosis and promotes the proliferation of lewis cells via RAGE/TLR4-dependent signal pathways. Scand J Immunol 79: 386-394.
45. Meghnani V, Vetter SW, Leclerc E (2014) RAGE overexpression confers a metastatic phenotype to the WM115 human primary melanoma cell line. Biochim Biophys Acta 1842: 1017-1027.
46. Sasahira T, Kirita T, Oue N, Bhawal UK, Yamamoto K, et al. (2008) High mobility group box-1-inducible melanoma inhibitory activity is associated with nodal metastasis and lymphangiogenesis in oral squamous cell carcinoma. Cancer Sci 99: 1806-1812.
47. Valencia JV, Mone M, Zhang J, Weetall M, Buxton FP, et al. (2004) Divergent pathways of gene expression are activated by the RAGE ligands S100b and AGE-BSA. Diabetes 53: 743-751.
48. Jules J, Maiguel D, Hudson BI (2013) Alternative splicing of the RAGE cytoplasmic domain regulates cell signaling and function. PLoS One 8: e78267.
49. Lin L, Zhong K, Sun Z, Wu G, Ding G (2012) Receptor for advanced glycation end products (RAGE) partially mediates HMGB1-ERKs activation in clear cell renal cell carcinoma. J Cancer Res Clin Oncol 138: 11-22.